子宫内膜异位症新药开发的基础研究  

Research Progress on Endometriosis Drugs Treatment

作　　者：余贵媛 金平[1] YU Gui-yuan JIN Ping(Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518028, Guangdong province, China)

机构地区：[1]南方医科大学附属深圳市妇幼保健院,广东省深圳市518028

出　　处：《国际妇产科学杂志》2016年第5期581-585,共5页Journal of International Obstetrics and Gynecology

基　　金：2013年深圳市科技计划项目研发基金(JCYJ20130402094134980);2015年深圳市科技计划项目基金(JCYJ20150402090412995);2015年深圳市卫生计生系统科研项目基金(201501034)

摘　　要：子宫内膜异位症(EMs)是常见的妇科慢性疾病,发病率高,治疗时间长,好发于生育年龄妇女,可引起慢性盆腔痛、痛经、性交痛和不孕等。目前针对EMs的药物、手术治疗等方案均有缺陷,药物治疗不良反应大、时间久,手术治疗复发率高,故如何提高疗效成为研究的热点。目前许多新的治疗药物正处于研究中,如促性腺激素释放激素拮抗剂(Gn RHA)、抗血管生成药物、抗炎药物、促凋亡和抗增殖药物、干细胞相关疗法等,目前为止,这些新药的基础研究已经有了一些新的进展,其中一些药物已经进入了临床Ⅲ期试验,疗效正在被观察中,这些新药有望成为EMs药物治疗的新里程碑,为EMs患者带来福音。综述EMs新药开发的基础研究成果。Endometriosis （EMs） is a common chronic gynecological disease with high incidence, and long treatment time. A lot of defects have been found within current treatment for EMs, such as drugs and surgical treatments, that medication has numerous side-effects while surgery has high recurrence rate. Therefore, devoting our effort to improving the curative effect of treatment is becoming a hot spot of research in this field. At present, many new treatments are being in the study, such as GnRH receptor antagonist, anti-angiogenesis drugs, anti-inflammatory drugs, the potential application of stem cell, etc. Some of these drugs have entered clinical phase of the study. Hence, the new research progress in endometriosis drugs treatment is reviewed in this article.

关 键 词：子宫内膜异位症 血管生成抑制剂 干细胞移植 药物疗法 

分 类 号：R711.71[医药卫生—妇产科学]